|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01498 PURAPHARM
Nominal 
0.315 0.000 (0.000%) Profitability Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| ROAA (%) | -4.998% | -4.544% | -11.404% | -10.819% | -9.446% |
| ROAE (%) | -29.148% | -26.804% | -51.555% | -36.437% | -26.692% |
| Return on Capital Employed (%) | -16.433% | -15.775% | -38.875% | -34.240% | -22.547% |
Margin Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Gross Profit Margin (%) | 53.600% | 53.689% | 53.244% | 58.630% | 64.184% |
| EBITDA Margin (%) | 9.189% | 12.855% | -6.504% | -10.448% | -6.123% |
| Pre-tax Profit Margin (%) | -10.238% | -7.628% | -25.147% | -26.599% | -17.767% |
| Net Profit Margin (%) | -10.480% | -9.275% | -26.073% | -26.829% | -18.478% |
Liquidity Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Current Ratio (X) | 0.474 X | 0.547 X | 0.612 X | 0.730 X | 0.918 X |
| Quick Ratio (X) | 0.267 X | 0.295 X | 0.305 X | 0.471 X | 0.669 X |
Leverage Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Total Liabilities / Total Assets(%) | 81.192% | 84.464% | 81.843% | 74.590% | 66.700% |
| Total Debt / Total Assets (%) | 50.614% | 50.824% | 50.330% | 49.499% | 44.114% |
| Net Debt / Total Assets (%) | 48.284% | 49.036% | 47.946% | 42.039% | 39.166% |
| Total Debt / Shareholders' Funds (%) | 269.107% | 327.127% | 277.200% | 194.804% | 132.474% |
| Long Term Debt / Shareholders' Funds (%) | 51.363% | 89.550% | 67.070% | 28.848% | 27.655% |
| Net Debt / Shareholders' Funds (%) | 256.715% | 315.622% | 264.066% | 165.445% | 117.614% |
| Net Cash / (Debt) ($) | (334.972M) | (350.965M) | (404.644M) | (427.326M) | (472.288M) |
| Net Cash / (Debt) per share ($) | (0.625) | (0.887) | (1.022) | (1.079) | (1.196) |
| Total Debt / Capital Employed (%) | 163.822% | 161.917% | 155.665% | 143.312% | 98.411% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Inventory Turnover (Day) | 260.655 Day | 308.540 Day | 333.837 Day | 333.188 Day | 267.419 Day |
| Receivables Turnover (Day) | 61.846 Day | 66.089 Day | 95.425 Day | 160.181 Day | 133.621 Day |
| Payables Turnover (Day) | 118.067 Day | 133.066 Day | 127.521 Day | 113.471 Day | 83.012 Day |
| Remarks: | Real time quote last updated: 27/03/2026 14:25 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD -35,223 |
| %Change | -0.609% |
| EPS / (LPS) | HKD -0.084 |
| NBV Per Share ($) | HKD 0.243 |